Citizens JMP lowered the firm’s price target on Integra LifeSciences (IART) to $25 from $35 and keeps an Outperform rating on the shares. Integra’s Q1 sales and earnings results were within guidance ranges, but expectations for Q2 were a bit below, the analyst tells investors in a research note. The firm views Monday’s 20% selloff on this news as overdone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences price target lowered to $15 from $19 at Truist
- Integra LifeSciences price target lowered to $13 from $25 at Wells Fargo
- Integra LifeSciences Reports Q1 2025 Financial Results
- Integra LifeSciences Earnings Call: Mixed Results Amid Challenges
- Morning Movers: Skechers surges following take-private deal